ARDELYX, INC. Other Noncash Income (Expense)
ARDELYX, INC. (ARDX) reported Other Noncash Income (Expense) of $1.26 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2024-05-02
- ARDELYX, INC. other noncash income (expense) for the quarter ending 2024-03-31 was $1.26M.
- ARDELYX, INC. other noncash income (expense) for the quarter ending 2023-12-31 was $1.45M.
- ARDELYX, INC. other noncash income (expense) for the quarter ending 2023-09-30 was $962.00K.
- ARDELYX, INC. other noncash income (expense) for the quarter ending 2023-06-30 was $1.02M.
- ARDELYX, INC. other noncash income (expense) for fiscal 2023 was $2.93M.
- ARDELYX, INC. other noncash income (expense) for fiscal 2022 was -$685.00K, a 201.03% decline from fiscal 2021.
- ARDELYX, INC. other noncash income (expense) for fiscal 2021 was $678.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.26M 10-Q · filed 2024-05-02 | $2.71M derived: sum of 2 quarters · filed 2024-05-02 | $3.67M derived: sum of 3 quarters · filed 2024-05-02 | $4.69M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.41M derived: sum of 2 quarters · filed 2024-02-22 | $3.43M derived: sum of 3 quarters · filed 2024-02-22 | $2.93M 10-K · filed 2024-02-22 |
| 2023-09-30 | $962.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $1.98M derived: sum of 2 quarters · filed 2023-10-31 | $1.48M 10-Q · filed 2023-10-31 | $972.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $521.00K 10-Q · filed 2023-08-02 | $10.00K derived: sum of 3 quarters · filed 2024-05-02 | -$28.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-03-31 | -$499.00K 10-Q · filed 2024-05-02 | -$1.01M derived: sum of 2 quarters · filed 2024-05-02 | -$1.05M derived: sum of 3 quarters · filed 2024-05-02 | |
| 2022-12-31 | -$511.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$549.00K derived: sum of 2 quarters · filed 2024-02-22 | -$685.00K 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$174.00K 10-Q · filed 2023-10-31 | ||
| 2022-06-30 | -$136.00K 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $678.00K 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |